MIR6737

Across TCGA pan-cancer cohorts, MIR6737 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated MIR6737 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR6737 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR6737 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LIHC, KIRP, and LUAD are the cancer types where MIR6737 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.398	0.782	<.001	81	view →
KIRP	DFS	Tertile	II,III,IV	0.169	0.702	<.001	72	view →
LUAD	OS	Tertile	All	0.628	0.823	<.001	51	view →
READ	DFS	Tertile	II,III,IV	0.171	0.527	.033	18	view →
LGG	DFS	Tertile	All	0.488	0.832	.002	15	view →
HNSC	DFS	Tertile	All	0.804	0.334	.023	15	view →
ESCA	DFS	Tertile	II,III,IV	0.356	0.547	.013	12	view →
PRAD	OS	Tertile	All	0.960	0.995	.011	12	view →
SKCM	DFS	Tertile	All	0.458	0.623	.036	6	view →
UCEC	DFS	Tertile	II,III,IV	0.566	0.830	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MIR6737–LIHC (OS)

Open the LIHC breakdown →